Cancer biologics refer to a substance used in the prevention, detection, or treatment of cancer and other disorders that is created from a living creature or its byproducts. Immunoglobulins, interleukins, and vaccinations are examples of biologic agents. A form of cancer treatment known as "biological therapy" employs the body's immune system to eradicate cancer cells. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancer, and others, and is distributed through various channels such as hospitals, clinics, and others. The cancer biologics market research report is one of a series of new reports from The Business Research Company that provides cancer biologics market statistics, including cancer biologics industry global market size, regional shares, competitors with a cancer biologics market share, detailed cancer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biologics industry. This cancer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer biologics market grew from $86.64 billion in 2022 to $96.33 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer biologics market is expected to grow from $140.88 billion in 2027 at a CAGR of 10.0%. The rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market's growth. Chronic disorders are diseases that persist over a long period and hinder the health of people with disabilities, and cancer is one of the most common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to the World Health Organization (WHO), in 2020, chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over the coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion, as they are proteins that are quickly digested and inactivated if given by mouth, so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis, and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates, but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers that help physicians decide the treatments for their patients by utilising physiological biomarkers for predicting performance. Predictive biomarkers study tumour growth in patients by analysing the major etiological factors, as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the most cost-effective treatment regimens, especially for the biologics based on gene therapy. According to the FDA approval process for new cancer treatments and biological products, the application for approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company-sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from several alternative sources. In May 2020, Boehringer Ingelheim, a Germany-based, research-driven pharmaceutical company, acquired Northern Biologics for an undisclosed amount. This acquisition would provide Boehringer Ingelheim with two additional assets to add to its existing cancer immunology portfolio that complement Northern Biologics' current offerings, supporting the company's goal to target "cold" tumours with synergistic combination methods. The acquisition includes Northern Biologics’ preclinical cancer antibody pipeline, which is expanding its immuno-oncology portfolio. Northern Biologics is a Canada-based clinical-stage biotechnology company. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co., Inc., Novartis, and Pfizer. North America was the largest region in the cancer biologics market in 2022. The Middle East is expected to be the fastest growing region in the global cancer biologics market during the forecast period. The regions covered in the global cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cancer biologics market consists of sales of cancer vaccines, cytokine therapy, and angiogenesis inhibitors. Values in this market are factory gate values which are the values of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Other Types 2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications 3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Orthrobiologic devices are implants composed of cells and proteins that are naturally found in the human body and that provide accelerated healing by stimulating efficient regrowth of musculoskeletal tissues, including bones, cartilage, tendons, and ligaments. The main product types of orthobiologics devices and equipment are demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and synthetic orthobiologics. Stem cell therapy is promoting the repair response of diseased, dysfunctional, or injured tissue using stem cells or their derivatives. The various applications involved are osteoarthritis and degenerative arthritis, soft-tissue injuries, fracture recovery, maxillofacial and dental applications, spinal fusion, trauma repair, and reconstructive surgery that are used by various end-users such as hospitals, orthopedic clinics, and others. The orthobiologics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides orthobiologics devices and equipment market statistics, including orthobiologics devices and equipment industry global market size, regional shares, competitors with a orthobiologics devices and equipment market share, detailed orthobiologics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the orthobiologics devices and equipment industry. This orthobiologics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global othobiologics devices and equipment market grew from $4.86 billion in 2022 to $5.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The othobiologics devices and equipment market is expected to grow from $6.85 billion in 2027 at a CAGR of 6.7%. The aging population profile of most countries contributed to the growth of orthobiologics devices and equipment market globally. According to the United Nations report, there were 962 million people aged over 60 across the globe, comprising 13% of the global population. The population aged over 60 is expected to grow at a rate of about 3% every year. The report further estimated that Europe had the highest percentage of the population aged over 60. The number of people globally over the age of 65 grew by 33%, according to estimates based on Population Reference Bureau data. The increase in the aging population has increased the patient pool of many orthopedic disorders and led to an increase in the demand for orthobiologics devices and equipment market. Rising incidences of post-surgical complications in patients implanted with orthobiologics devices are one of the major restraints in the orthobiologics devices and equipment market. Surgical procedures with orthobiologics grafts, implants, and devices have become increasingly common in recent years. Major postoperative complications include device failures, bleeding, postoperative infections, immune responses, and rejections. These procedures may develop post-surgery complications which refer to the development of any unwanted or unexpected conditions related to the device, graft, or implant. These complications may vary with the type of procedure, implant, graft, or device, the experience of the surgeon, improper device testing procedures before market launch, device location in the body, and the health and biological response of the individual. The increasing post-operative complications and device failures can limit the orthobiologics devices and equipment market. Biodegradable implants are increasingly being used in orthobiologics treatment and trauma orthopedic surgeries. Biodegradable implants are used to replace a missing biological structure, support a damaged biological structure, and enhance the existing bone structure. Biodegradable products such as re-absorbable polymers composed of polyglycolic acid and polylactic acid manufactured in the form of plates, screws, and pins are replacing traditional devices like plates and screws which are more expensive. Surgeons are preferring biodegradable implants to replace conventional implants, as biodegradable implants can be engineered to provide temporary support for bone fractures, can degrade at a rate matching new tissue formation, eliminate the need for the second surgery, and are highly useful in fracture fixation in children with less implant-related infections. For instance, Stryker Corp. offers orthobiologics such as bone repair biodegradable products that are used in bone regeneration and bone healing, soft tissue regeneration, and muscle connection to bone Regulatory changes are likely to lead to increased costs relating to new product development and supply of orthobiologics devices. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. In November 2017, the USFDA has announced a comprehensive regenerative medicine policy framework to facilitate innovation. This policy deals with the manufacture of tissues, human cells, and cellular and tissue-based products other procedures to prevent the introduction, transmission, and spread of communicable diseases. Orthobiologics such as stem cell therapies are approved through this framework. The potential loss of revenue due to delays in product release, additional costs incurred by the time-consuming approval processes, and changing regulations puts a strain on investments relating to orthobiologics devices development. Major players in the orthobiologics devices and equipment market are Medtronic, Arthrex Inc., DePuy Synthes (A Subsidiary of Johnson & Johnson), Stryker Corporation, Zimmer Biomet, Bioventus LLC., Baxter International Inc., Integra Lifesciences Holding Corporation, Nuvasive Inc., and Sanofi. North America was the largest region in the global orthobiologics devices and equipment market in 2022. Western Europe was the second-largest region in the orthobiologics devices and equipment market. The regions covered in global orthobiologics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The counties covered in the orthobiologics devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The orthrobiologic devices market consists of sales of demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and other synthetic orthobiologics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global orthobiologics devices and equipment market is segmented - 1) By Product Type: Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cell Therapy, Plasma-Rich Protein, Viscosupplementation, Bone Morphogenetic Protein, Synthetic Orthobiologics 2) By Application: Osteoarthritis and Degenerative Arthritis, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications, Spinal Fusion, Trauma Repair, Reconstructive Surgery 3) By End Use: Hospitals, Orthopedic Clinics, Other End Users

A biosimilar refers to a medication that closely resembles a biologic medication in both structure and function. A biologic drug, however, is a treatment created using a biological system, such as yeast, bacteria, or animal cells. A biological product is considered "biosimilar" if it is extremely similar to and bears no discernible clinical differences from an FDA-approved reference product already in use. The main therapy types are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors, and tumour necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. Interleukins are a family of cytokines produced by lymphocytes, monocytes, macrophages, and a few other cells. They play an important role in immune system regulation. The various diseases treated include asthma, Crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others, by vaccines, proteins and peptides, monoclonal antibodies, and others. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The oral biologics market research report is one of a series of new reports from The Business Research Company that provides oral biologics market statistics, including oral biologics industry global market size, regional shares, competitors with an oral biologics market share, detailed oral biologics market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics industry. This oral biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oral biologics & biosimilar drugs market grew from $4.91 billion in 2022 to $5.94 billion in 2023 at a compound annual growth rate (CAGR) of 21.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral biologics & biosimilar drugs market is expected to grow from $11.77 billion in 2027 at a CAGR of 18.6%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market. Stringent regulations imposed on the approval of biosimilar are anticipated to hinder the growth of oral biologics and the biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug for biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. For instance, according to 2021 Biosimilars Trend Report, in year 2020, the FDA approved 3 biosimilars. The COVID-19 epidemic and the ensuing closure most likely slowed the approval of biosimilars. In contrast, the FDA authorised 10 biosimilars in 2019, bringing the US total to 26. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar markets. The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in August 2020, Biocon Biologics India Ltd., an India-based fully integrated global biosimilars organization, in partnership with Mylan, a US-based biosimilar company, has launched Semglee, insulin glargine injection in the U.S. Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca PLC., Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan PLC., Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline PLC., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche. North America was the largest region in the oral biologics and biosimilar drugs market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global oral biologics and biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oral biologics and biosimilar market consists of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oral biologics & biosimilar drugs market is segmented - 1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors 2) By Disease: Asthma, Crohn'S Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis, and Others 3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, and Other Molecule Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. Oral biologics and biosimilar market comprise biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious conditions and are used to treat chronic diseases such as diabetes, arthritis, and cancer. The main therapy types of oral biologics and biosimilar lymphocytes are modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. The various diseases include asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others that are treated by molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and other therapies. These are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The oral biologics and biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilars market statistics, including oral biologics and biosimilars industry global market size, regional shares, competitors with a oral biologics and biosimilars market share, detailed oral biologics and biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilars industry. This oral biologics and biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oral biologics and biosimilars market size will grow from $5.37 billion in 2022 to $6.47 billion in 2023 at a compound annual growth rate (CAGR) of 20.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral biologics and biosimilars market size is expected to grow from $13.68 billion in 2027 at a CAGR of 20.6%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the growth of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics stimulate the immune system's attack on cancer cells, aiding the body's natural defenses in getting rid of the disease-causing cells. According to a United Nations article, a US-based intergovernmental organization, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. It is anticipated that chronic disease will account for nearly 60% of all deaths worldwide. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market. Stringent regulations imposed on the approval of biosimilar are anticipated to hinder the growth of oral biologics and the biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar markets. The creation of new insulin biosimilar is a key trend gaining popularity in the oral biologics and biosimilar market. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance,In November 2021, Biocon, an India-based biopharmaceutical company launched inter-changeable biosimilar insulin. These products help to control high blood sugar in pediatric patients with type 1 diabetes and adults with type 2 diabetes and are available in a vial and prefilled pen presentations. These are interchangeable for the reference brand, Lantus (insulin glargine), allowing for substitution at the pharmacy counter. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit. Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, and Emisphere Technologies. North America was the largest region in the oral biologics and biosimilar drugs market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oral biologics & biosimilar drugs market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oral biologics and biosimilar market consist of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oral biologics and biosimilars market is segmented - 1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, and Tumor Necrosis Factor-Alpha Inhibitors 2) By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Other Diseases 3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, and Other Molecule Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. This therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global therapeutic proteins market grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The therapeutic proteins market is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic protein drugs developed using protein engineering technologies and approved by the FDA in the past five years. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic protein market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic protein drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global therapeutic protein market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy. The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others. The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global bi-specific mabs market grew from $5.13 billion in 2022 to $6.72 billion in 2023 at a compound annual growth rate (CAGR) of 31.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bi-specific mabs market is expected to grow from $13.16 billion in 2027 at a CAGR of 18.3%. The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in February 2022, according to the World Health Organization, a Switzerland-based international public health agency of the United Nations, cancer will be the leading cause of deaths across the globe, causing almost 10 million fatalities in 2020, or almost one in every six deaths. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. Additionally, in October 2022, according to the Centers for Disease Control and Prevention, chronic diseases will be among the most prevalent diseases, with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively. The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographispaniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales and hence impacts the bi-specific MAbS market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market shortly. Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment. In August 2020, AbCellera, a biotechnology firm based in Canada, completed the acquisition of the OrthoMab bispecific platform from Dualogics for an undisclosed amount. The acquisition integrated OrthoMab into AbCellera’s existing technology stack, which provided the industry with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies Dualogics is a US-based biotechnology company specialized in protein engineering for improving antibody therapeutics. Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott. North America was the largest region in the bi-specific MAbS market in 2022. The regions covered in the global bi-specific MAbs or bispecific monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global bi-specific MAbs or bispecific monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global BI-specific MAbS market is segmented - 1)By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597 2)By Product Type: In Vivo, In Vitro 3)By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Other Indications 4)By End Use: Hospitals, Research Institutes, Other End-Users

The agricultural biologicals are used to safeguard plants against pests, improve yield and prevent diseases. Agricultural biologicals refer to microorganisms or biochemical derived from naturally occurring microorganisms, plant extracts, insects, or other organic matter. It is combined with synthetic crop protection products as an integrated management solution. Agricultural biologics aims to provide a holistic approach for growers to maximize crop yields, improve quality, and minimize pest resistance. The main types of agricultural biologicals are biopesticides, biofertilizers, and biostimulants. Biopesticides are biological pesticides that are derived from biological materials such as plants, animals, bacteria, and certain minerals. These are derived from microbials, macrobials, biochemicals, other sources and applied by foliar spray, soil treatment, seed treatment, and post-harvest mode of application. The various applications include cereals and grains, oilseed and pulses, fruits and vegetables, turf and ornamentals, and other applications. The agricultural biologicals market research report is one of a series of new reports from The Business Research Company that provides agricultural biologicals market statistics, including agricultural biologicals industry global market size, regional shares, competitors with an agricultural biologicals market share, detailed agricultural biologicals market segments, market trends and opportunities, and any further data you may need to thrive in the agricultural biologicals industry. This agricultural biological market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global agricultural biologics market size grew from $10.52 billion in 2022 to $12.11 billion in 2023 at a compound annual growth rate (CAGR) of 15.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The agricultural biologics market size is expected to grow to $21.07 billion in 2027 at a CAGR of 14.8%. The increasing incidences of pest outbreaks contributed to the growth of the agricultural biological market. Pest outbreaks refer to an increasing sporadic and large population of pests that are economically harmful to crops and human beings. Due to pest outbreaks, the threats to crops cause 10–40% losses to major food crops such as corn, wheat, and rice cost to the global economy. The pests cause damage to crops and significantly impair growers' productivity and destroy cropland. For instance, in August 2020, an article published by BBC, a UK based broadcasting company included a locust invasion that swept over farms in rural Kenya, Ethiopia, Uganda, Somalia, Eritrea, India, Pakistan, Iran, Yemen, Oman, and Saudi Arabia which estimated a loss of $2.5 billion in crop damage. Hence, increasing pest outbreaks drove the agriculture biological market. Strategic collaboration and partnerships are the key trends gaining popularity in the agriculture biological market. Strategic collaboration is increasingly being done among market players to develop and commercialize agricultural biological products for the betterment of growers and each other businesses. For instance, In October 2021, UPL, an Indian manufacturer, and distributor of bio-solutions announced the collaboration with Chr. Hansen, a Denmark-based bioscience company helps farmers worldwide to fight pest diseases and improve crop quality and yields. Furthermore, in August 2021, Marrone Bio Innovations Inc., a US-based provider of sustainable protection and plant health solutions announced the collaboration with Terramera, a Canada-based agri-tech company to exchange their technological and biological expertise to increase the performance of MBI's crop protection products and accelerate product development. In October 2020, Syngenta Group, a Switzerland-based agrichemical company acquired Valagro for an undisclosed amount. With this acquisition, Syngenta Crop will provide farmers with the more complimentary product and technology choices and underpins its determination to make agriculture more resilient and sustainable. Valagro is a US-based biological company and a producer of innovative agricultural biologicals. Major players in the agricultural biologicals market are Syngenta AG, The Dow Chemical Company, Bayer AG, BASF SE, Isagro Company, Marrone Bio Innovations, Koppert Biological Systems, Novozymes A/S, Gowan Company LLC, Vegalab SA, Lallemand Inc., Valent Bioscience, T Stanes & Co Limited, Arysta LifeScience, and Camson Bio Technologies. North America was the largest region in the agricultural biologicals market in 2022. Asia-Pacific is expected to be the fastest-growing region in the market. The regions covered in the agricultural biologicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the agricultural biologicals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The agricultural biologicals market consists of sales of agricultural biologicals from sources such as plant extracts and minerals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global agricultural biologics market is segmented - 1) By Type: Biopesticides, Biofertilizers, Biostimulants 2) By Source: Microbials, Macrobials, Biochemicals, Other Sources 3) By Mode of Application: Foliar Spray, Soil Treatment, Seed Treatment, Post-Harvest 4) By Application: Cereals And Grains, Oilseed And Pulses, Fruits And Vegetables, Turf And Ornamentals, Other Applications

The vaccines market consists of sales of vaccines and related services. This industry includes establishments that produce anti-infective vaccines, autoimmunity vaccines and vaccines for cancer and other diseases. Vaccines create antibody-antigen reaction that helps in attaining resistance to the disease causing organism. Vaccines include recombinant vaccines, conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines and others. The main types of vaccines market are anti-infective vaccines, autoimmunity, others (cancer and others). Anti-infective vaccines are used to prevent infectious diseases. The various technologies of vaccines include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines that are administered through intramuscular (IM), subcutaneous (SC), oral, and others. The different valance of vaccines market are monovalent and multivalent which are distributed by institutional sale, hospital pharmacies, and retail pharmacies. The global vaccines market size is expected to decline from $92.70 billion in 2021 to $105.20 billion in 2022 at a compound annual growth rate (CAGR) of 13.5%. The slow decline is mainly due to the outbreak of COVID-19 that has led to deferment of immunocompromised treatments. The vaccines market is expected to reach $290.67 billion in 2026 at a CAGR of 28.9%. Rising awareness on immunization and vaccination benefits in emerging markets is consistently driving the global vaccines market growth. World Health Organization (WHO) is taking initiatives to increase awareness of immunization through global vaccine action plan (GVAP) and global Immunization vision and strategy (GIVS). They aim to strengthen routine immunization, control morbidity and mortality from vaccine preventable diseases and help countries to immunize more people with a greater range of vaccines. The Organization accomplishes this work through its biological programme, the WHO Collaborating Centers, and the WHO Expert Committee on Biological Standardization (ECBS). In 2019, according to the WHO, approximately 85% of infants globally (116 million infants) received 3 doses of diphtheria-tetanus-pertussis (DTP3) vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. Furthermore, 125 countries reached at least 90% coverage of the DTP3 vaccine in 2019. The vaccines market growth is limited due to severe shortage of skilled healthcare professionals for developing biologics drugs which requires specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. According to a study conducted by the consulting firm Mercer, the United States will face significant healthcare worker shortages in the coming decade. The firm predicts a shortage of more than 400,000 home health aides and 29,400 nurse practitioners by 2025. This shortage also led to rise in competition and salaries for the limited talent pool available for biologics talent, thereby further limiting growth of the market. The vaccines market has been witnessing multiple strategic initiatives and mergers and acquisitions in the recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. For instance, in February 2019, Bharat Biotech acquired Chiron Behring Vaccines, a clinical biotechnology company, one of the leading manufacturers of rabies vaccines across the globe. Similarly, in September 2021, Sanofi, a France based healthcare company, acquired Translate Bio, an mRNA therapeutics company developing potentially transformative medicines to treat diseases caused by protein or gene dysfunction, for a deal amount of $3.2 billion to develop mRNA vaccines. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favourable interest rates globally. The Food and Drug Administration (FDA) is the National Regulatory Authority (NRA) in the United States responsible for assuring quality, safety, and effectiveness of all vaccines for human use. Center for Biologics Evaluation and Research (CBER) within the US FDA is responsible for regulating vaccines market. Governments across the world are encouraging the research and development of biologics in order to develop more targeted therapies and vaccines for various diseases. In May 2014, the US FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. In 2016, FDA also removed a rule (Section 610.21 of the FDA code) which specified minimal potency limits for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. In May 2020, Novavax, a US-based late-stage biotechnology company specialising in next-generation vaccines, announced the acquisition of Praha Vaccines, a subsidiary of the Cyrus Poonawalla Group, for a deal amount of $167 million. With this acquisition, Novavax increased its annual capacity of more than one billion doses of antigen for NVX-CoV2373, Novavax's COVID-19 vaccine candidate. Praha Vaccines was a subsidiary of the Cyrus Poonawalla Group, which is the parent company of Serum Institute of India and specialises in the production of immuno-biologicals. Major players in the vaccines market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Ltd., Biological E Limited, BiondVax Pharmaceuticals Ltd, Bristol-Myers Squibb, Inovio Pharmaceuticals Inc., Madison Vaccines Incorporated, NOVARTIS AG, Novavax Inc., Panacea Biotec, Sinovac Biotech Ltd., Valneva SE, and VBI Vaccine Inc. North America was the largest region in the vaccines market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global vaccines market is segmented - 1) By Type: Anti-Infective Vaccines, Autoimmunity, Others (Cancer and Others) 2) By Technology: Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines 3) By Route of Administration: Intramuscular (IM), Subcutaneous (SC), Oral, Others 4) By Valence: Monovalent, Multivalent 5) By Distribution Channel: Institutional Sale, Hospital Pharmacies, Retail Pharmacies